Obeda/ Usema (USV)
by Dr Reddy's + USV · DCGI approved 2025 (first DCGI approval)
| Active ingredient | Semaglutide (GLP-1 receptor agonist) |
| Indication | Type 2 Diabetes |
| Manufacturer | Dr Reddy's Laboratories Ltd |
| DCGI status | Approved 2025 (first DCGI approval) |
| Price (MRP) | ₹4,200/month |
| Format | Prefilled disposable pen 4 weekly doses per pen · 2 mg and 4 mg strengths |
| Prescription | Schedule H — required |
How Obeda compares
Obeda was the first generic semaglutide to receive DCGI approval in India — predating the broader March 2026 patent-expiry wave. Approved for type 2 diabetes only, it carries Dr Reddy's SemaKare patient-support programme: injection-technique training, tele-support, and adherence tracking. USV co-markets the same molecule as Usema under licence.
About Dr Reddy's + USV
Dr Reddy's Laboratories is one of India's largest pharma companies and a major global generics exporter. Plans to launch in 87 countries position the Obeda franchise for international expansion. USV, the licensing partner, is one of India's leading diabetes-focused pharma companies with a strong endocrinology-prescriber relationship.
GLP-1 Check is informational, not a medical diagnosis. Semaglutide is a Schedule H drug in India and requires a prescription from a registered medical practitioner. Always consult a qualified physician before starting any treatment.